Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO-COMBAT XL: XL092 and Cemiplimab in BRAF V600E-wildtype Anaplastic Thyroid Cancer
NCT06902376Phase 1Recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Jun 2025
- Primary completion
- Mar 2028
- Modality
- Fragment-Derived Small Molecules, Immune Checkpoint Inhibitors, Antibody Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zanzalintinib and cemiplimab in anaplastic thyroid cancer (ATC), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoints: Complete gross resection at 12 weeks and Non-hematologic treatment related adverse events at 2 years. Started Jun 2025; status: recruiting.
02
Drugs
zanzalintinibcemiplimab
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on NCT06902376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06902376.